Switch to:
Also traded in: Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 61.16
SGMO's Cash-to-Debt is ranked higher than
51% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. SGMO: 61.16 )
Ranked among companies with meaningful Cash-to-Debt only.
SGMO' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.71  Med: No Debt Max: No Debt
Current: 61.16
Equity-to-Asset 0.69
SGMO's Equity-to-Asset is ranked higher than
53% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. SGMO: 0.69 )
Ranked among companies with meaningful Equity-to-Asset only.
SGMO' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.39  Med: 0.87 Max: 0.99
Current: 0.69
0.39
0.99
Debt-to-Equity 0.02
SGMO's Debt-to-Equity is ranked higher than
92% of the 487 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. SGMO: 0.02 )
Ranked among companies with meaningful Debt-to-Equity only.
SGMO' s Debt-to-Equity Range Over the Past 10 Years
Min: 0  Med: 0.02 Max: 1.42
Current: 0.02
0
1.42
Debt-to-EBITDA -0.08
SGMO's Debt-to-EBITDA is ranked lower than
99.99% of the 209 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. SGMO: -0.08 )
Ranked among companies with meaningful Debt-to-EBITDA only.
SGMO' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.08  Med: -0.06 Max: -0.06
Current: -0.08
-0.08
-0.06
Interest Coverage N/A
SGMO's Interest Coverage is ranked lower than
54% of the 496 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SGMO: N/A )
Ranked among companies with meaningful Interest Coverage only.
SGMO' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: N/A
N/A
No Debt
Piotroski F-Score: 4
Altman Z-Score: 6.80
Beneish M-Score: -2.83
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -161.75
SGMO's Operating Margin % is ranked lower than
60% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. SGMO: -161.75 )
Ranked among companies with meaningful Operating Margin % only.
SGMO' s Operating Margin % Range Over the Past 10 Years
Min: -374.23  Med: -119.18 Max: -58.38
Current: -161.75
-374.23
-58.38
Net Margin % -157.66
SGMO's Net Margin % is ranked lower than
60% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. SGMO: -157.66 )
Ranked among companies with meaningful Net Margin % only.
SGMO' s Net Margin % Range Over the Past 10 Years
Min: -369.58  Med: -114.89 Max: -57.59
Current: -157.66
-369.58
-57.59
ROE % -32.49
SGMO's ROE % is ranked higher than
51% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. SGMO: -32.49 )
Ranked among companies with meaningful ROE % only.
SGMO' s ROE % Range Over the Past 10 Years
Min: -52.56  Med: -33.13 Max: -16.09
Current: -32.49
-52.56
-16.09
ROA % -24.99
SGMO's ROA % is ranked higher than
52% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. SGMO: -24.99 )
Ranked among companies with meaningful ROA % only.
SGMO' s ROA % Range Over the Past 10 Years
Min: -47.56  Med: -28.49 Max: -13.76
Current: -24.99
-47.56
-13.76
ROC (Joel Greenblatt) % -737.28
SGMO's ROC (Joel Greenblatt) % is ranked lower than
60% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. SGMO: -737.28 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
SGMO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2186.87  Med: -1671.55 Max: -737.28
Current: -737.28
-2186.87
-737.28
3-Year Revenue Growth Rate -13.90
SGMO's 3-Year Revenue Growth Rate is ranked lower than
67% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. SGMO: -13.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
SGMO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -37.3  Med: -2.15 Max: 67.4
Current: -13.9
-37.3
67.4
3-Year EBITDA Growth Rate 29.50
SGMO's 3-Year EBITDA Growth Rate is ranked higher than
79% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. SGMO: 29.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
SGMO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -23.7  Med: 5.25 Max: 104.7
Current: 29.5
-23.7
104.7
3-Year EPS without NRI Growth Rate 28.60
SGMO's 3-Year EPS without NRI Growth Rate is ranked higher than
80% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. SGMO: 28.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
SGMO' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -25.2  Med: 0.15 Max: 184.4
Current: 28.6
-25.2
184.4
GuruFocus has detected 4 Warning Signs with Sangamo Therapeutics Inc SGMO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» SGMO's 30-Y Financials

Financials (Next Earnings Date: 2018-02-28)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

SGMO Guru Trades in Q4 2016

Paul Tudor Jones 65,800 sh (New)
Chuck Royce 751,100 sh (+40.10%)
Jim Simons 321,819 sh (-45.87%)
» More
Q1 2017

SGMO Guru Trades in Q1 2017

Chuck Royce 751,100 sh (unchged)
Paul Tudor Jones Sold Out
Jim Simons Sold Out
» More
Q2 2017

SGMO Guru Trades in Q2 2017

Paul Tudor Jones 26,507 sh (New)
Steven Cohen 357,705 sh (New)
Chuck Royce 751,100 sh (unchged)
» More
Q3 2017

SGMO Guru Trades in Q3 2017

Joel Greenblatt 26,695 sh (New)
Steven Cohen 693,300 sh (+93.82%)
Paul Tudor Jones 31,009 sh (+16.98%)
Chuck Royce 478,465 sh (-36.30%)
» More
» Details

Insider Trades

Latest Guru Trades with SGMO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2017-09-30 New Buy0.01%$8.4 - $14.75 $ 14.7034%26,695
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:XKRX:102940, XPAR:STAGR, NAS:NDRM, NAS:DERM, NAS:ESPR, SZSE:300147, NAS:NTLA, NAS:LXRX, NAS:ARNA, NAS:ATNX, SAU:2070, NAS:ENTA, ROCO:4174, NAS:XNCR, NAS:AKCA, NAS:AMRI, SHSE:603566, SZSE:300255, NAS:EDIT, XMCE:ROVI » details
Traded in other countries:GBY.Germany, SGMO.Switzerland, 0R1D.UK,
Headquarter Location:USA
Sangamo Therapeutics Inc is a clinical stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Sangamo Therapeutics Inc was incorporated in the State of Delaware on June 22, 1995. The Company is engaged in translating ground-breaking science into genomic therapies that transform patients' lives using the company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Its proprietary zinc finger DNA-binding proteins (ZFP) technology enables efficient and highly specific genome editing and gene regulation, and are developing genome editing and gene therapies for the treatment of genetically tractable diseases.

Top Ranked Articles about Sangamo Therapeutics Inc

Sangamo Announces Treatment of First Patient in Landmark Phase 1/2 Clinical Trial Evaluating In Vivo Genome Editing for MPS II
Market Trends Toward New Normal in Domino's Pizza, Sangamo Therapeutics, Entergy, Agilent Technologies, Zayo Group, and Republic Services – Emerging Consolidated Expectations, Analyst Ratings
Sangamo Therapeutics Announces Third Quarter 2017 Conference Call And Webcast
Sangamo Therapeutics Announces Presentations At 2017 Annual Congress Of The European Society Of Gene And Cell Therapy
Sangamo And Bioverativ Announce FDA Acceptance Of IND Application For ST-400 -- A Gene-Edited Cell Therapy Candidate -- To Treat Beta-Thalassemia
Sangamo Therapeutics Announces Participation At Upcoming Investor And Industry Conferences
Sangamo Therapeutics Announces Presentation At The 2017 Cantor Fitzgerald Global Healthcare Conference
Sangamo Presents T Cell Engineering Capabilities at Immuno-Oncology Summit
Sangamo Therapeutics Announces Presentations At Upcoming Investor Conferences
Sangamo And Pfizer Announce First Patient Receives Treatment In Phase 1/2 Clinical Trial Evaluating SB-525 Investigational Gene Therapy For Hemophilia A

Ratios

vs
industry
vs
history
Price-to-Owner-Earnings 213.05
SGMO's Price-to-Owner-Earnings is ranked lower than
94% of the 145 Companies
in the Global Biotechnology industry.

( Industry Median: 38.46 vs. SGMO: 213.05 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
SGMO' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 150  Med: 194.93 Max: 231.16
Current: 213.05
150
231.16
PB Ratio 6.64
SGMO's PB Ratio is ranked lower than
68% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. SGMO: 6.64 )
Ranked among companies with meaningful PB Ratio only.
SGMO' s PB Ratio Range Over the Past 10 Years
Min: 1.47  Med: 4.12 Max: 11.13
Current: 6.64
1.47
11.13
PS Ratio 34.27
SGMO's PS Ratio is ranked lower than
75% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. SGMO: 34.27 )
Ranked among companies with meaningful PS Ratio only.
SGMO' s PS Ratio Range Over the Past 10 Years
Min: 4.84  Med: 19.23 Max: 78.78
Current: 34.27
4.84
78.78
Price-to-Free-Cash-Flow 72.78
SGMO's Price-to-Free-Cash-Flow is ranked lower than
86% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 36.07 vs. SGMO: 72.78 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
SGMO' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 48.98  Med: 66.58 Max: 78.96
Current: 72.78
48.98
78.96
Price-to-Operating-Cash-Flow 59.77
SGMO's Price-to-Operating-Cash-Flow is ranked lower than
85% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 25.45 vs. SGMO: 59.77 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
SGMO' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 39.13  Med: 54.67 Max: 64.84
Current: 59.77
39.13
64.84
EV-to-EBIT -19.25
SGMO's EV-to-EBIT is ranked lower than
99.99% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. SGMO: -19.25 )
Ranked among companies with meaningful EV-to-EBIT only.
SGMO' s EV-to-EBIT Range Over the Past 10 Years
Min: -45.3  Med: -9.2 Max: -0.9
Current: -19.25
-45.3
-0.9
EV-to-EBITDA -19.73
SGMO's EV-to-EBITDA is ranked lower than
99.99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. SGMO: -19.73 )
Ranked among companies with meaningful EV-to-EBITDA only.
SGMO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -46.3  Med: -9.4 Max: -0.9
Current: -19.73
-46.3
-0.9
EV-to-Revenue 31.13
SGMO's EV-to-Revenue is ranked lower than
71% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. SGMO: 31.13 )
Ranked among companies with meaningful EV-to-Revenue only.
SGMO' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.3  Med: 15 Max: 75.8
Current: 31.13
2.3
75.8
Current Ratio 5.64
SGMO's Current Ratio is ranked higher than
64% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. SGMO: 5.64 )
Ranked among companies with meaningful Current Ratio only.
SGMO' s Current Ratio Range Over the Past 10 Years
Min: 5.06  Med: 11.57 Max: 55.31
Current: 5.64
5.06
55.31
Quick Ratio 5.64
SGMO's Quick Ratio is ranked higher than
66% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. SGMO: 5.64 )
Ranked among companies with meaningful Quick Ratio only.
SGMO' s Quick Ratio Range Over the Past 10 Years
Min: 5.06  Med: 11.57 Max: 55.31
Current: 5.64
5.06
55.31
Days Sales Outstanding 38.66
SGMO's Days Sales Outstanding is ranked higher than
60% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. SGMO: 38.66 )
Ranked among companies with meaningful Days Sales Outstanding only.
SGMO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 1.14  Med: 27.89 Max: 93.6
Current: 38.66
1.14
93.6

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.40
SGMO's 3-Year Average Share Buyback Ratio is ranked higher than
77% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. SGMO: -4.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SGMO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -61.2  Med: -9.1 Max: -1.1
Current: -4.4
-61.2
-1.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 8.03
SGMO's Price-to-Net-Cash is ranked lower than
52% of the 543 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. SGMO: 8.03 )
Ranked among companies with meaningful Price-to-Net-Cash only.
SGMO' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.96  Med: 4.03 Max: 17.78
Current: 8.03
0.96
17.78
Price-to-Net-Current-Asset-Value 7.78
SGMO's Price-to-Net-Current-Asset-Value is ranked lower than
52% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 7.12 vs. SGMO: 7.78 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
SGMO' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.93  Med: 3.92 Max: 17.45
Current: 7.78
0.93
17.45
Price-to-Tangible-Book 6.68
SGMO's Price-to-Tangible-Book is ranked lower than
60% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. SGMO: 6.68 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
SGMO' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.89  Med: 3.76 Max: 12.57
Current: 6.68
0.89
12.57
Price-to-Median-PS-Value 1.78
SGMO's Price-to-Median-PS-Value is ranked lower than
85% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. SGMO: 1.78 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SGMO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.3  Med: 1.27 Max: 9.59
Current: 1.78
0.3
9.59
Earnings Yield (Greenblatt) % -5.20
SGMO's Earnings Yield (Greenblatt) % is ranked higher than
55% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. SGMO: -5.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SGMO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -110.2  Med: -10.9 Max: -2.2
Current: -5.2
-110.2
-2.2

More Statistics

Revenue (TTM) (Mil) $32.41
EPS (TTM) $ -0.69
Beta3.43
Short Percentage of Float11.25%
52-Week Range $2.65 - 17.06
Shares Outstanding (Mil)84.52

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 21 16 12 12
EPS ($) -1.00 -1.26 -1.37 -1.43
EPS without NRI ($) -1.00 -1.26 -1.37 -1.43
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}